Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This is what Dan said
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Apr 07, 2021 6:51pm
253 Views
Post# 32954196

RE:RE:This is what Dan said

RE:RE:This is what Dan said
StockingUp21 wrote:
Marky1 wrote:

I’m running the overall BD…and there are 3,000 US institutional investors; we’re knocking them off one by one...
Hes in full control and there's no one else I'd like to see guiding ATE to its golden futur

 


 

 

Can you ask did this just start or happening since august and how many have they met with? I don't think it's working



In August they were probably looking at making smaller deals - to bring in the cash.  Now we know they ended up partnering with China.

They were not interested in discussing with Big Pharma at that time - I got the sense that ATE wasn't ready for those discussions.

You are better off going to January's shareholder update and to the different virtual conferences Dan spoke at ... to see when the Institutional Investor became important.

You say it isn't working ... and I'm saying they likely won't be buying until we're on the NAZ.  Hope that help you - chicken and egg scenario, kinda.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities